Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Chapman, Ros ^a   Jongwe, Tsungai Ivai ^a   Douglass, Nicola ^a   Chege, Gerald ^a   Williamson, Anna Lise ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MVA VACCINE; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; SECONDARY IMMUNIZATION; VIRION;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; HEK293 CELLS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MICE; VACCINES, DNA; VIRAL VACCINES; VIRION;

EID: 85014964532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173352     Document Type: Article

References (32)

1. AIDS by the numbers 2016. http://www.unaids.org/sites/default/files/media-asset/AIDS-by-thenumbers-2016-en.pdf.
2. Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, et al. Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Mol Ther. 2016; 24(2):375-84. doi: 10.1038/mt.2015.210 PMID: 26581160
3. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010; 16 (3):319-U116. doi: 10.1038/nm.2089 PMID: 20173752
4. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell. 2013; 155(3):531-9. doi: 10.1016/j.cell.2013.09.061 PMID: 24243013
5. Santra S, Liao HX, Zhang RJ, Muldoon M, Watson S, Fischer W, et al. Mosaic Vaccines Elicit Cd8+T Cell Responses in Monkeys That Confer Immune Coverage of Diverse Hiv Strains. J Med Primatol. 2010; 39(4):282-.
6. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJR, et al. Mosaic HIV-1 Gag Antigens Can Be Processed and Presented to Human HIV-Specific CD8(+) T Cells. J Immunol. 2011; 186(12):6914-24. doi: 10.4049/jimmunol.1004231 PMID: 21576505
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New Engl J Med. 2009; 361(23):2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557
8. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003; 77(11):6305-13. doi: 10.1128/JVI.77.11.6305-6313.2003 PMID: 12743287
9. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2016; 34(4):413-23. doi: 10.1016/j.vaccine.2015.11.062 PMID: 26691569
10. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2005; 79(2):771-9. doi: 10.1128/JVI.79.2.771-779.2005 PMID: 15613305
11. McCormack S, Stohr W, Barber T, Bart PA, Harari A, Moog C, et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008; 26(25):3162-74. doi: 10.1016/j.vaccine.2008.02.072 PMID: 18502003
12. Tanzer FL, Shephard EG, Palmer KE, Burger M, Williamson AL, Rybicki EP. The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine. Virology journal. 2011; 8:51-422X-8-51.
13. Williamson AL, Rybicki EP. Justification for the inclusion of Gag in HIV vaccine candidates. Expert Review of Vaccines. 2016; 15(5):585-98. doi: 10.1586/14760584.2016.1129904 PMID: 26645951
14. Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, et al. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016; 23(6):496-506. doi: 10.1128/CVI. 00717-15 PMID: 27098021
15. Jongwe TI, Chapman R, Douglass N, Chetty S, Chege G, Williamson AL. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice. PLoS One. 2016; 11(7):e0159141. doi: 10.1371/journal.pone.0159141 PMID: 27427967
16. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine. 1998; 16(4):426-35. PMID: 9607066
17. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Research and Human Retroviruses. 2003; 19(2):133-44. doi: 10.1089/088922203762688649 PMID: 12639249
18. Fisher RD, Chung HY, Zhai Q, Robinson H, Sundquist WI, Hill CP. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell. 2007; 128(5):841-52. doi: 10.1016/j.cell.2007.01. 035 PMID: 17350572
19. Chapman R, Stutz H, JacobsWJr., Shephard E, Williamson AL. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice. PLoS One. 2013; 8(8):e71601. doi: 10.1371/journal.pone.0071601 PMID: 23977084
20. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol. 2006; 87(Pt 2):399-410. doi: 10.1099/vir.0.81379-0 PMID: 16432028
21. Columb MO, Sgadai S. Multiple comparisons. Current Anaesthesia & Critical Care. 2006; 17:233-6.
22. Sundquist WI, Krausslich HG. HIV-1 Assembly, Budding, and Maturation. Csh Perspect Med. 2012; 2 (7).
23. Datta SAK, Clark PK, Fan LX, Ma BY, Harvin DP, Sowder RC, et al. Dimerization of the SP1 Region of HIV-1 Gag Induces a Helical Conformation and Association into Helical Bundles: Implications for Particle Assembly. J Virol. 2016; 90(4):1773-87.
24. Rueda P, Moron G, Sarraseca J, Leclerc C, Casal JI. Influence of flanking sequences on presentation efficiency of a CD8(+) cytotoxic T-cell epitope delivered by parvovirus-like particles. Journal of General Virology. 2004; 85:563-72. doi: 10.1099/vir.0.19525-0 PMID: 14993639
25. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8(+) T-cell epitopes. J Virol. 2006; 80(10):4717-28. doi: 10.1128/JVI.80.10.4717-4728.2006 PMID: 16641265
26. Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, et al. Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. Plos One. 2015; 10(4).
27. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Review of Vaccines. 2012; 11(2):189-209. doi: 10.1586/erv.11.188 PMID: 22309668
28. Harari A, Bart PA, Stohr WF, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205(1):63-77. doi: 10.1084/jem.20071331 PMID: 18195071
29. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007; 13 (1):46-53. doi: 10.1038/nm1520 PMID: 17173051
30. Asbach B, Kliche A, Kostler J, Perdiguero B, Esteban M, Jacobs BL, et al. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016; 90(8):4133-49. doi: 10.1128/JVI.03135-15 PMID: 26865719
31. Ellenberger D, Wyatt L, Li B, Buge S, Lanier N, Rodriguez IV, et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02-AG) DNA/MVA vaccines expressing mature and immxature VLPs. Virology. 2005; 340(1):21-32. doi: 10.1016/j.virol.2005.06.014 PMID: 16023165
32. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, et al. DNA/MVA vaccine for HIV type 1: Effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. Aids Research and Human Retroviruses. 2004; 20(12):1335-47. doi: 10.1089/aid.2004.20.1335 PMID: 15650426